Bupropion for the Treatment of Methamphetamine Dependence

National Institute on Drug Abuse (NIDA)5 sites in 1 country150 target enrollmentJuly 2003

ConditionsAmphetamine-Related Disorders

DrugsBupropion

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Amphetamine-Related Disorders
Sponsor: National Institute on Drug Abuse (NIDA)
Enrollment: 150
Locations: 5
Primary Endpoint: Severity addiction
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Detailed Description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Registry

clinicaltrials.gov

Start Date

July 2003

End Date

June 2005

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

National Institute on Drug Abuse (NIDA)

Eligibility Criteria

Inclusion Criteria

•Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
•Subject must be willing to comply with study procedures.
•Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
•Be able to comply with protocol requirements